Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09248-6
Abstract: ObjectiveThe efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported;… read more here.
Keywords: treatment; ocrelizumab versus; efficacy; multiple sclerosis ... See more keywords
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01186-z
Abstract: Introduction Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted. Methods The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the… read more here.
Keywords: treatment; highly active; cladribine tablets; multiple sclerosis ... See more keywords
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Sign Up to like & getrecommendations! Published in 2025 at "Neurology and Therapy"
DOI: 10.1007/s40120-025-00782-2
Abstract: Cladribine tablets (CladT) for relapsing multiple sclerosis help reset the immune system with short treatment courses over 2 years. This analysis of MAGNIFY-MS contrasted clinical outcomes with changes in immune cells, proteins and genes over… read more here.
Keywords: multiple sclerosis; research blood; cladribine tablets; summary research ... See more keywords
Daclizumab: A Review in Relapsing Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0708-2
Abstract: Daclizumab (Zinbryta®; previously known as daclizumab high-yield process) is a therapeutic monoclonal antibody that has recently been approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Daclizumab is a humanized IgG1… read more here.
Keywords: daclizumab; multiple sclerosis; review relapsing; daclizumab review ... See more keywords
To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2019.101908
Abstract: BACKGROUND The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into… read more here.
Keywords: sclerosis; treat; treatment; multiple sclerosis ... See more keywords
Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago.
Sign Up to like & getrecommendations! Published in 2020 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2020.102253
Abstract: A 26-year-old man, with five years of highly active deteriorating relapsing multiple sclerosis (MS), unresponsive to conventional therapy, was treated with autologous hematopoietic stem-cell transplantation (AHSCT) 13 years ago. Since then the patient had no… read more here.
Keywords: sclerosis; autologous hematopoietic; highly active; multiple sclerosis ... See more keywords
Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13919
Abstract: Cladribine tablets have shown significant efficacy for the treatment of relapsing multiple sclerosis, a chronic and debilitating immune‐mediated disorder. This study was conducted to examine acute and/or cumulative effects of cladribine tablets 10 mg (3.5… read more here.
Keywords: cladribine tablets; multiple sclerosis; relapsing multiple; effects cladribine ... See more keywords
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/17562864251351760
Abstract: Background: Cladribine, an oral prodrug, penetrates the blood–brain barrier, impacting biomarkers of disease progression within the central nervous system. Objectives: Describe disease activity in cladribine tablets (CladT)-treated people with highly active relapsing multiple sclerosis (pwRMS)… read more here.
Keywords: multiple sclerosis; clinicaltrials gov; baseline; results magnify ... See more keywords
Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2020.595547
Abstract: Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical… read more here.
Keywords: treatment relapsing; multiple sclerosis; anti cd20; relapsing multiple ... See more keywords
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of comparative effectiveness research"
DOI: 10.57264/cer-2023-0016
Abstract: Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for annualised relapse rate (ARR)… read more here.
Keywords: meta analysis; efficacy; network meta; multiple sclerosis ... See more keywords